- BioNTech is the company behind the Pfizer vaccine which is being used globally
- Was approved in the UK on December 2 and given to first person December 8
- New jab uses mRNA to stop MS patients’ immune systems attacking neurons
- Studies in mice show it stopped disease progression and also reversed some loss of motor function
January 12, 2021
The experts behind the BioNTech coronavirus jab have developed another vaccine which they claim cures multiple sclerosis (MS) in mice.
The new MS vaccine works in a similar way to the coronavirus vaccine, manufactured in conjunction with US pharmaceutical giant Pfizer.
A piece of genetic material known as mRNA is inserted into a person’s arm and forces the body’s own cells to produce a protein that confers immunity.
In the case of the coronavirus vaccine, this protein mimics the virus’s protruding spike, kickstarting the immune system to start making antibodies.
If a person later contracts the coronavirus, the immune system rapidly creates antibodies again and fights the infection before it can take hold or spread.
In the case of the MS vaccine, the mRNA technology stops the body’s own immune system from attacking neurons in the brain and spinal cord which prevents the eventual loss of bodily function.
Clinical trials on mice revealed the jab cured the condition, stopped disease progression and restored some motor skills which had already been lost.
Clinical trials on mice revealed the MS jab cured the condition, stopped disease progression and restores some motor skills which had already been lost (stock)